In this context, we hypothesized that combining basal insulin with a GLP1-RA in early T2DM may provide a strategy that could enhance the achievability of the desired metabolic outcomes of improved beta-cell function and diabetes remission, while limiting the risks of hypoglycemia and weight gain. This evidence concerns the gene GLP1R and Hypoglycemia.